Introduction
============

Atrial fibrillation (AF), characterized by rapid and chaotic electrical activity in the atria with consequent deterioration of atrial mechanical function, is the most common form of cardiac arrhythmia seen in clinical practice, accounting for about one-third of hospitalizations for cardiac rhythm disturbances [@B1]. The prevalence of AF is estimated to be approximately 1% in the general population, and increases markedly with advancing age, rising from less than 1% in individuals under 60 years of age to nearly 10% in subjects aged 80 years and above [@B1]. According to a report from the Framingham Heart Study, the lifetime risk of developing AF is about 25% in males and females aged over 40 years [@B2]. This supraventricular tachycardia, often resulting in an irregular ventricular response, is a major cause of substantial cardiovascular morbidity and mortality. AF is associated with a two-fold increase in the risk of death [@B3], and confers a five-fold increased risk of thromboembolic stroke [@B4]. The annual incidence of stroke attributable to AF also increases with age, ranging from 1.5% of people in their fifties to 23.5% in octogenarians [@B4],[@B5]. In addition, AF may contribute to degraded quality of life, reduced exercise tolerance, impaired cognitive function, tachycardia-induced cardiomyopathy, and left ventricular dysfunction or even congestive heart failure [@B1],[@B6]. AF commonly occurs in association with various cardiac and systemic conditions, such as coronary artery disease, congenital heart disease, rheumatic heart disease, cardiac surgery, cardiomyopathy, myocarditis, pulmonary heart disease, hypertension, hyperthyroidism, and even electrolyte imbalance [@B1],[@B7]-[@B9]. However, in 2% to 45% of people with AF, there are no obvious pathologic substrates or risk factors, and such AF is termed lone AF [@B1], [@B10]. Among patients with lone AF, at least 15% present with a positive family history, so diagnosed as familial AF [@B11]. Increasing genetic epidemiological studies from around the world have consistently demonstrated the substantial familial aggregation of AF and a significantly increased risk for AF in the close relatives of patients with AF, indicating a strong genetic basis for AF [@B12]-[@B17]. Genome-wide genetic linkage analysis with highly polymorphic microsatellite markers mapped AF-susceptibility loci on human chromosomes 10q22, 6q14-16, 11p15.5, 5p15, 10p11-q21, and 5p13, of which AF-causing mutations in two genes, including *KCNQ1* on chromosome 11p15.5 and *NUP155* on chromosome 5p13, were identified and functionally characterized [@B18]. Analyses of candidate genes unveiled a long list of AF-associated genes, including *KCNQ1, KCNE1, KCNE2, KCNA5, KCND3, KCNJ2, KCNH2, SCN5A, GJA1, GJA5, NPPA,* and *SCN1-4B* [@B18]-[@B21]. However, these established AF-related genes seem to be relatively rare causes of AF, and in an overwhelming majority of patients, the genetic defects predisposing to AF remain to be unknown.

Emerging evidence suggests that anomalous embryological development of the cardiovascular system, especially the pulmonary venous myocardium, is a common and key anatomic substrate for AF [@B22]. Research in human developmental biology reveals the essential role of several transcription factors, including NKX2-5, GATA4, GATA5 and GATA6, in the cardiovascular genesis [@B23], and multiple mutations in *GATA4*, *GATA5* and *GATA6* have been causally implicated in the pathogenesis of AF [@B24]-[@B33]. The expression and function of NKX2-5 overlap with those of the GATA family during cardiovascular development, especially in regulation of target gene expression synergistically with GATA4, which makes *NKX2-5* a logical candidate gene for AF [@B34].

Materials and Methods
=====================

Ethics
------

This study was carried out in compliance with the ethical principles of the revised Declaration of Helsinki (Somerset West, Republic of South Africa, 1996). The research protocol was reviewed and approved by the local institutional ethics committee (the ethical approval number for cases and controls: KS1101; the date for the approval: April 12, 2011) and written informed consent was obtained from all participants prior to the study.

Study subjects
--------------

A cohort of 146 unrelated patients with lone AF was prospectively recruited from the Chinese Han population for the present study. In addition, if an *NKX2-5* mutation was identified in a patient, the mutation carrier\'s available family members were also included. A total of 700 ethnically matched unrelated healthy individuals were enlisted as controls. All the subjects were assessed with regard to clinical and family history. Comprehensive physical examination, routine biological test, standard 12-lead electrocardiogram and transthoracic echocardiogram were performed. The clinical data including medical records, electrocardiogram and echocardiography reports were collected and reviewed. The study subjects were clinically classified as having AF using a consistently applied set of definitions [@B11].

Genetic screening
-----------------

Peripheral venous blood specimens from all participants were prepared. Genomic DNA was isolated from blood lymphocytes of participants using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA), according to the manufacturer\'s instructions. The referential genomic DNA sequence of *NKX2-5* was derived from [GenBank]{.ul} (GenBank ID: NG_013340.1), a gene sequence database at the National Center for Biotechnical Information (NCBI; <http://www.ncbi.nlm.nih.gov/>). With the aid of the online Primer 3 program (<http://frodo.wi.mit.edu/>), the primer pairs used to amplify the coding exons (exon 1-2) and intron-exon boundaries of *NKX2-5* by polymerase chain reaction (PCR) were designed as previously described [@B35]. The *NKX2-5* gene was screened for potential sequence variations by PCR-sequencing in 146 unrelated patients with lone AF. The available family members of the mutation carriers and the 700 unrelated healthy control individuals were also genotyped for *NKX2-5*. The PCR was performed using HotStar Taq DNA Polymerase (Qiagen, Hilden, Germany) on a Veriti Thermal Cycler (Applied Biosystems, Foster, CA, USA) with standard conditions and concentrations of reagents. Amplified products were purified with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Amplicons were bi-directionally sequenced on an ABI PRISM 3130 XL DNA Analyzer (Applied Biosystems, Foster, CA, USA) with BigDye^®^ Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems, Foster, CA, USA). The sequencing primers were the same as designed previously for specific region amplifications. DNA sequences were viewed and analyzed with the DNA Sequencing Analysis Software v5.1 (Applied Biosystems, Foster, CA, USA). Each variant was corroborated by bi-directional re-sequencing of an independent PCR-generated amplicon from the same subject and met the quality control threshold with a call rate exceeding 99%. For identified sequence variants, several standard databases including the Human Gene Mutation Database (HGMD; <http://www.hgmd.cf.ac.uk/>) and the NCBI′s Single Nucleotide Polymorphism (SNP; <http://www.ncbi.nlm.nih.gov/snp>) and PubMed Databases (<http://www.ncbi.nlm.nih.gov/pubmed>) were queried to confirm their novelty.

Alignment of multiple NKX2-5 protein sequences
----------------------------------------------

The conservation of the amino acids of NKX2-5 was evaluated by aligning human NKX2-5 to chimpanzee, monkey, dog, cow, mouse, rat, chicken, and zebrafish NKX2-5 using the HomoloGene and Show Multiple Alignment links on the NCBI\'s web site (<http://www.ncbi.nlm.nih.gov/homologene>).

Prediction of the disease-causing potential of NKX2-5 sequence variations
-------------------------------------------------------------------------

The disease-causing potential of *NKX2-5* sequence variations was predicted by MutationTaster (an online program at website <http://www.mutationtaster.org>) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>), automatically giving a probability score for each alteration to be either pathogenic or benign.

Expression plasmids and site-directed mutagenesis
-------------------------------------------------

The recombinant expression plasmids NKX2-5-pEFSA and pSSRa-GATA4, and the atrial natriuretic factor (ANF)-luciferase reporter plasmid, which contains the 2600-bp 5\'-flanking region of the *ANF* gene, namely ANF(-2600)-Luc, were kindly provided by Dr. Ichiro Shiojima, from the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan. Each of the identified mutations was introduced into the wild-type *NKX2-5*using a QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) with a complementary pair of primers. The mutants were sequenced to confirm the desired mutations and to exclude any other sequence variations.

Luciferase reporter gene assays
-------------------------------

COS-7 cells were cultured in DMEM supplemented with 10% fetal calf serum. The ANF(-2600)-Luc reporter construct and an internal control reporter plasmid pGL4.75 (hRluc/CMV, Promega, Madison, WI, USA) were used in transient transfection assays to examine the transcriptional activation function of the NKX2-5 mutants. COS-7 cells were transfected with 0.4 μg of wild-type or mutant NKX2-5-pEFSA expression vector, 1.0 μg of ANF(-2600)-Luc reporter construct, and 0.04 μg of pGL4.75 control reporter vector using PolyFect Transfection Reagent (Qiagen, Hilden, Germany). For co-transfection experiments, 0.2 μg of wild-type NKX2-5-pEFSA, 0.2 μg of mutant NKX2-5-pEFSA or empty vector pEFSA, 1.0 μg of ANF(-2600)-Luc, and 0.04 μg of pGL4.75 were used. Firefly luciferase and Renilla luciferase activities were measured with the Dual-Glo luciferase assay system (Promega, Madison, WI, USA) 48h after transfection. The activity of the *ANF* promoter was presented as fold activation of Firefly luciferase relative to Renilla luciferase. Three independent experiments were performed at minimum for wild-type and mutant NKX2-5.

Given that NKX2-5 and GATA4 activate several cardiac gene promoters including the *ANF* promoter in a synergistic manner [@B36], similar experiments were performed in the presence of GATA4 to explore the synergistic effects of NKX2-5 and GATA4 on the *ANF* promoter. By using PolyFect Transfection Reagent (Qiagen, Hilden, Germany), COS-7 cells were transfected with 0.2 μg of wild-type NKX2-5-pEFSA, or 0.2μg of pSSRa-GATA4, or 0.2 μg of wild-type NKX2-5-pEFSA in combination with 0.2μg of pSSRa-GATA4, in the presence of 1.0 μg of ANF(-2600)-Luc and 0.02 μg of pGL4.75. For co-transfection assay, 0.1 μg of wild-type NKX2-5-pEFSA and 0.1 μg of each mutant NKX2-5-pEFSA were used, in the presence of 0.2μg of pSSRa-GATA4, 1.0 μg of ANF(-2600)-Luc, and 0.02 μg of pGL4.75.

Statistics
----------

Data are presented as means ± SD. Continuous variables were tested for normal distribution and Student\'s unpaired t test was used to make comparison of numeric variables between two groups. Comparison of the categorical variables between two groups was performed using Pearson\'s χ^2^ test or Fisher\'s exact test when appropriate. A two-tailed p value \< 0.05 was considered statistically significant.

Results
=======

Clinical characteristics of the study population
------------------------------------------------

A cohort of 146 unrelated patients with lone AF was enrolled and clinically investigated. A total of 700 ethnically matched unrelated healthy individuals were also clinically assessed. None of them had overt traditional risk factors for AF. There was no significant difference between patient and control groups in baseline characteristics including age, gender, body mass index, serum lipid, blood pressure, fasting blood glucose, left atrial dimension, left ventricular ejection fraction, heart rate at rest, as well as life style (data not shown). During five years of follow-up, seven patients were also diagnosed with hypertension in accordance to the criterion that the average systolic or diastolic blood pressure (two readings made after five minutes of rest in sitting position) was ≥140 mm Hg or ≥90 mm Hg, respectively, but at the time of initial diagnosis of AF, their blood pressures were normal. Besides, other traditional risk factors for AF such as structural heart disease, diabetes mellitus and hyperthyroidism were also absent at the time of first diagnosis of AF. The baseline clinical characteristics of the 146 patients with lone AF are summarized in Table [1](#T1){ref-type="table"}.

NKX2-5 mutations
----------------

Two heterozygous mutations in *NKX2-5* were identified in 2 of 146 unrelated patients with lone AF, with a mutational prevalence of roughly 1.37%. Specifically, a substitution of cytosine (C) for guanine (G) in the first nucleotide of codon 21 (c.61G\>C), predicting the replacement of glutamic acid (E) with glutamine (Q) at amino acid position 21 (p.E21Q), was identified in a patient from family 1. A substitution of G for adenine (A) at coding nucleotide 538 (c.538A\>G), corresponding to the replacement of threonine (T) with alanine (A) at amino acid position 180 (p.T180A), was detected in a patient from family 2. The sequence chromatograms showing the detected heterozygous *NKX2-5* mutations of c.61G\>C and c.538A\>G compared with their control sequences are shown in Figure [1](#F1){ref-type="fig"}. A schematic diagram of NKX2-5 showing the structural domains and the locations of the identified mutations is presented in Figure [2](#F2){ref-type="fig"} [@B37]. The identified mutations were absent in the control individuals. The p.T180A mutation was not found in standard databases like HGMD, SNP, and PubMed, indicating a novel mutation. Although the p.E21Q mutation was previously identified in patients with congenital atrial septal defect or tetralogy of Fallot [@B38]-[@B40], it has not been associated with AF before.

Genetic scan of the relatives of each mutation carrier demonstrated that the mutation was present in all affected family members alive, but absent in unaffected family members examined. Analysis of the pedigrees showed that in each family the mutation co-segregated with AF transmitted in an autosomal dominant pattern with complete penetrance. The pedigree structures of the families are illustrated in Figure [3](#F3){ref-type="fig"}. The phenotypic characteristics and results of genetic screening of the affected family members available are listed in Table [2](#T2){ref-type="table"}.

Interestingly, congenital atrial septal defect was confirmed by the early echocardiogram and medical records of previous catheter-based closure in patient I-1 from family 2. In addition, two *NKX2-5* polymorphisms, c.63A\>G and c.606C\>G, were observed in both AF patients and control individuals. However, there was no significant difference in either of the two allele frequencies between the AF patient and healthy control groups. All the sequence variants and their allele frequencies are listed in Table [3](#T3){ref-type="table"}.

Multiple NKX2-5 sequence alignments
-----------------------------------

Alignment of multiple NKX2-5 proteins across species showed that the altered amino acids were completely conserved evolutionarily, underscoring their functional importance, as shown in Figure [4](#F4){ref-type="fig"}.

Disease-causing potential of NKX2-5 sequence variations
-------------------------------------------------------

The *NKX2-5* mutations were both predicted to be disease-causing by MutationTaster, with p values of 0.98 and 1.00 for c.61G\>C and c.538A\>G, respectively, and they were predicted to be possibly damaging by PolyPhen-2, with a score of 0.95 (sensitivity: 0.79; specificity: 0.95) for c.61G\>C and 1.00 (sensitivity: 0.14; specificity: 0.99) for c.538A\>G, implying that mutated *NKX2-5* might contribute to the development of AF in these families. No SNPs in the altered regions were found in the MutationTaster database.

Transcriptional activity of the mutant NKX2-5
---------------------------------------------

The transcriptional activation characteristics of the mutated NKX2-5 in COS-7 cells were assayed using the promoter of *ANF*, one of the target genes regulated by NKX2-5, as a driver of luciferase reporter. The activity of the *ANF* promoter was expressed as fold activation of Firefly luciferase relative to Renilla luciferase. The same amounts of wild-type (0.4 μg), E21Q-mutant (0.4 μg), and T180A-mutant NKX2-5 (0.4 μg) activated the *ANF* promoter by \~13-fold, \~6-fold, and \~3-fold, respectively, with p values of 0.002 for E21Q-mutant and 0.001 for T180A-mutant when compared with wild-type NKX2-5. When the same amount of wild-type NKX2-5 (0.2 μg) was cotransfected with E21Q-mutant (0.2 μg) or T180A -mutant (0.2 μg), the induced activation of the *ANF* promoter was \~7-fold or \~5-fold, with p values of 0.003 for E21Q-mutant and 0.002 for T180A-mutant when compared with wild-type NKX2-5 (0.4 μg). These results suggest that the NKX2-5 mutations are associated with significantly reduced transactivational activity compared with their wild-type counterpart (Figure [5](#F5){ref-type="fig"}).

In addition, as shown in Figure [6](#F6){ref-type="fig"}, biological analysis demonstrated that NKX2-5 and GATA4 activated the ANF promoter in a synergistic manner. Cotransfection with wild-type NKX2-5 (0.2 μg) and GATA4 (0.2 μg) showed much stronger activation (\~25-fold) of the *ANF* promoter than single transfection with 0.2 μg of wild-type NKX2-5 (\~10-fold; p = 0.0004) or 0.2 μg of GATA4 (\~3-fold; p = 0.0001). The synergistic activation (\~18-fold) by E21Q-mutant NKX2-5 and GATA4 was significantly reduced by \~28% compared with that by wild-type NKX2-5 and GATA4 (p = 0.0094). The T180A-mutant had no synergistic effect on GATA4-induced activation of the *ANF* promoter (\~3-fold), with a p value of 0.0001 when compared with wild-type NKX2-5 and GATA4.

Discussion
==========

In the present study, two heterozygous NKX2-5 mutations, p.E21Q and p.T180A, were identified in two families with lone AF, respectively. In each family the mutation co-segregated with AF and was absent in the 700 control individuals. A cross-species alignment of multiple NKX2-5 protein sequences displayed that the altered amino acids were completely conserved evolutionarily. Functional analyses revealed that both mutations were associated with a significantly decreased transcriptional activity. Therefore, it is likely that these two NKX2-5 variants predispose carriers to AF.

NKX2-5 has been identified in various vertebrate species from Xenopus to humans. It is highly expressed in the early cardiac progenitor cells in both primary and secondary heart fields during embryogenesis and continues to be expressed at a high level in the heart through adulthood, playing a pivotal role in normal cardiovascular development and maturation [@B41]. Human *NKX2-5* gene maps to chromosome 5q34 and consists of two exons coding for a protein of 324 amino acids [@B42]. As shown in Figure [2](#F2){ref-type="fig"}, the NKX2-5 protein has a highly conserved structure composed of the N-terminal TN domain, the homeodomain (HD), and the C-terminal NK2-specific domain (NK). The HD is centrally located at amino acid positions 138-197 and contains a helix-turn-helix motif that recognizes and binds to the specific consensus DNA sequence 5\'-T(C/T)AAGTG-3\' [@B43]. The TN and NK domains function to regulate the transcriptional activity, and the HD is involved in nuclear translocation, DNA binding, and interaction with other transcription factors as well [@B44]. The NKX2-5 mutations p.E21Q and p.T180A identified in this study are located in TN and HD, respectively, and may influence the transcriptional activity of NKX2-5 by direct transcriptional inhibition or by interfering with its nuclear distribution or DNA-binding ability.

Previous studies have substantiated that NKX2-5 is an upstream regulator of several target genes expressed in the heart during embryogenesis including the genes that encode ANF, brain natriuretic peptide and α-cardiac actin [@B45]. Therefore, the functional characteristics of an NKX2-5 mutation can be explored by analysis of the transcriptional activity of the *ANF*promoter in cells transfected with NKX2-5 mutant in contrast to its wild-type counterpart. In this study, the functional roles of the two NKX2-5 mutations identified in lone AF patients were analyzed by transcriptional activity assays and the results showed a significantly decreased transcriptional activity on a downstream gene. These findings support that dysfunctional NKX2-5 resulted from mutations is potentially an alternative pathogenic mechanism underlying AF.

The findings that functionally impaired NKX2-5 predisposes to AF may be partially ascribed to the abnormally developed pulmonary vein myocardium. The pulmonary venous vessels are ensheathed by a layer of myocardium referred to as pulmonary myocardial sleeve, which has been implicated in the initiation and perpetuation of AF by several projected arrhythmogenic mechanisms including enhanced intrinsic pacemaker activity and liability to reentrance [@B46]-[@B48]. Genetic-labeling lineage tracing studies have shown that NKX2-5 is expressed in the atria as well as pulmonary myocardium and is indispensible for the localized formation of the sinoatrial node during embryogenesis. As a suppressor of the sinoatrial node lineage gene program, NKX2-5 may confine pacemaker activity to the sinoatrial and atrioventricular nodes. In a hypomorphic model with reduced NKX2-5 protein, the pulmonary cardiomyocytes shifted to connexin40-negative, HCN4-positive cells, resembling a nodal phenotype with pacemaker activity [@B47]. In *NKX2-5* knockout mouse embryos, *HCN4* was activated along the entire embryonic heart tube; whereas *connexin40* (*Cx40*) expression was inhibited, and ectopic pacemaker cells were present throughout the heart tube [@B48]. Hence, NKX2-5 loss-of-function mutation presumably contributes to formation of the pulmonary myocardium sleeve and switch of the pulmonary myocardium to a sinoatrial node-like phenotype, yielding an atrial arrhythmogenic substrate that facilitates AF.

It has been verified that some downstream genes are regulated by NKX2-5, and mutations in multiple target genes have been linked to AF, including the genes encoding ANF [@B49], cardiac voltage-gated sodium channel pore-forming alpha subunit (SCN5A) [@B50]-[@B53], gap junction protein Cx40 [@B54], and connexin43 (Cx43) [@B55]. Therefore, mutated NKX2-5 may confer susceptibility to AF by reducing the expression of some target genes.

Association of NKX2-5 mutation with AF in humans was investigated previously. Ritchie and colleagues screened*NKX2-5*in 160 unrelated index patients with familial AF and identified one novel heterozygous mutant (p.F145S) in a proband, with a mutational prevalence of around 0.63%. In this kindred the proband presented with early-onset paroxysmal AF. The proband\'s father also presented with lone AF in his 40s, and his brother, who carries the variant, has not been diagnosed with AF at age 52 years [@B56]. The same mutation was also detected in 1 of 110 unrelated index patients with familial AF by Huang *et al.*, with a mutational prevalence of about 0.91%, which co-segregated with AF in the family with complete penetrance. Functional analysis demonstrated that the F145S-mutant NKX2.5 was associated with significantly decreased transcriptional activity [@B57]. Xie and co-workers scanned *NKX2-5*in 136 unrelated patients with idiopathic AF and discovered two novel heterozygous NKX2-5 mutations (p.N19D and p.F186S) in two patients, respectively, with a mutational prevalence of approximately 1.47%. Functional assays revealed that the mutant NKX2-5 proteins were associated with significantly reduced transcriptional activity [@B58]. Boldt *et al.* also sequenced *NKX2-5*in 96 unrelated patients with idiopathic AF but did not find any mutation [@B59]. These studies suggest that *NKX2-5* mutations are a relatively rare cause of AF.

It was interesting that congenital atrial septal defect was documented in an AF patient carrying p.T180A mutation of NKX2-5. Similarly, congenital cardiovascular malformations were previously confirmed in AF patients carrying NKX2-5 mutations. Gutierrez-Roelens *et al.* sequenced *NKX2-5* in seven unrelated patients with atrial septal defect and/or atrioventricular conduction block, and discovered one novel heterozygous mutation (p.Y256X) in an index patient. In the proband\'s family, all the five mutation carriers had atrioventricular block, of which three mutation carriers had also AF and cardiac structural anomalies [@B60]. Watanabe *et al.* performed genetic analysis of *NKX2-5* in two unrelated families with atrial septal defect and atrioventricular block, and found two novel deletion frameshift mutations (p.E72Afs and p.P77Ffs). In the family with p.E72Afs mutation, there were five family members who harbored the mutation, of which one had lone AF as the only phenotype, another had atrial septal defect and atrioventricular block, and the other three had atrial septal defect, atrioventricular block, and AF [@B61]. Moreover, mutations in functionally synergistic partners of NKX2-5, including GATA4, GATA5 and GATA6, were also implicated in various congenital cardiovascular deformities with or without the presence of AF [@B24],[@B28],[@B31],[@B62],[@B63]. Considering some congenital cardiac structural defects may close spontaneously, we cannot rule out the possibility that some mutation carriers with lone AF had minor cardiac septal defects that closed shortly after birth on their own. These observations imply that a subset of "lone" AF may share a common genetic origin with congenital heart disease.

Notably, a long list of NKX2-5 mutations were previously linked to a wide variety of congenital cardiovascular malformations, including atrial septal defect, ventricular septal defect, tetralogy of Fallot, double outlet right ventricle, L-transposition of the great artery, and hypoplastic left heart syndrome without AF, of which several mutations, including the p.E21Q mutation identified in present study, were also observed in unaffected family members [@B37]-[@B40],[@B64],[@B65]. The pronounced variability in clinical presentation or penetrance of the genotypes may be explained by the following reasons. Firstly, AF occurs as rarely as a few times in a lifetime for some AF patients [@B66], suggesting that a longer duration of electrocardiographic monitoring is needed to record paroxysmal AF in these patients. Next, AF occurs more commonly in older patients, and these carriers may not be old enough to develop the disease. Thirdly, genomic imprinting results in preferential expression of the paternal or maternal allele of a certain gene, highlighting the effect of proband [@B67]. Fourthly, the nature of a mutation (loss-of-function, dominant-negative, or gain-of-function effect) and its temporal and spatial effect during cardiac development (germline or somatic) are a potential explanation for this phenomenon [@B65], [@B68]. Fifthly, different genetic backgrounds, including possibly common SNPs altering AF susceptibility, contribute to the variable penetrance of the AF-linked genotype [@B56]. Finally, mutations like p.E21Q may be a genetic risk factor predisposing to AF, rather than a direct cause of AF, and environmental risk factors may be required for the onset of AF.

In conclusion, the current study expands the spectrum of NKX2-5 mutations linked to AF and provides additional evidence that functionally compromised NKX2-5 may be involved in the pathogenesis of AF, implying the potential application to the early prophylaxis and personalized therapy of this common arrhythmia.
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![Sequence electropherograms showing the *NKX2-5* mutations in contrast to their corresponding controls. The arrow indicates the heterozygous nucleotides of G/C and A/G in the probands from families 1 (**A**) and 2 (**B**), respectively (mutant) or the homozygous nucleotides of G/G (**A**) and A/A (**B**) in the corresponding control individuals (wild-type). The rectangle denotes the nucleotides comprising a codon of *NKX2-5*.](ijmsv11p0554g001){#F1}

![Schematic representation of NKX2-5 protein structure with the atrial fibrillation (AF)-related mutations indicated. The mutations identified in patients with lone atrial fibrillation are shown above the structural domains. NH2 means amino-terminus; TN, transcriptional activation domain; HD, homeodomain; NK, NK2-specific domain; and COOH, carboxyl-terminus.](ijmsv11p0554g002){#F2}

![Pedigree structures of the families with lone atrial fibrillation. Families are designated as family 1 and family 2, respectively. Family members are identified by generations and numbers. Squares indicate male family members; circles, female members; closed symbols, affected members; open symbols, unaffected members; arrows, probands; \'\'+\'\', carriers of the heterozygous mutations; and \'\'-\'\', non-carriers.](ijmsv11p0554g003){#F3}

![Alignment of multiple NKX2-5 protein sequences across species. The altered amino acids of p.E21 and p.T180 are completely conservative evolutionarily among various species.](ijmsv11p0554g004){#F4}

![Functional defects caused by NKX2-5 mutations. Activation of atrial natriuretic factor promoter driven luciferase reporter in COS-7 cells by NKX2-5 wild-type (WT), E21Q-mutant, or T180A-mutant, alone or in combination, demonstrated significantly reduced transactivational activity by mutant proteins. Experiments were performed in triplicate, and mean and standard deviations are shown. \*\* and \* represent p \< 0.0005 and p \< 0.001, respectively, when compared with wild-type NKX2-5.](ijmsv11p0554g005){#F5}

![Reduced synergistic transcriptional activation by mutant NKX2-5 and GATA4. The synergistic activation by E21Q-mutant NKX2-5 and GATA4 was significantly reduced compared with that by wild-type NKX2-5 and GATA4. The E21Q-mutant NKX2-5 had significantly reduced synergistic effect while the T180A-mutant had no synergistic effect on GATA4-induced activation of the atrial natriuretic factor promoter. Experiments were performed in triplicate, and mean and standard deviations are shown. \* represents p \< 0.01 and \*\* represents p \< 0.001, when compared with wild-type NKX2-5 and GATA4.](ijmsv11p0554g006){#F6}

###### 

Baseline demographics*and clinical*characteristics of the*study population.*

  Parameters                                              Statistics
  ------------------------------------------------------- ------------
  **Baseline demographics**                               
  Age at first diagnosis of atrial fibrillation (years)   44 ± 8
  Male (n, %)                                             89 (61)
  Body mass index (kg/m^2^)                               23 ± 1
  Left ventricular ejection fraction (%)                  62 ± 5
  Left atrial diameter (mm)                               36 ± 3
  **Personal history of atrial fibrillation (n, %)**      
  Type of atrial fibrillation at presentation             
  Paroxysmal                                              97 (66)
  Persistent                                              32 (22)
  Permanent                                               17 (12)
  History of cardioversion                                110 (75)
  Positive family history of atrial fibrillation          68 (47)
  **Medical history (n, %)**                              
  History of syncope                                      14 (10)
  History of pacemaker                                    10 (7)
  Thromboembolic complication                             9 (6)
  Hyperlipidemia                                          8 (5)
  Arterial hypertension                                   7 (5)
  Diabetes                                                5 (3)
  **Medications (n, %)**                                  
  Amiodarone                                              105 (72)
  Warfarin                                                84 (58)
  Digitalis                                               23 (16)
  Aspirin                                                 18 (12)
  Beta-blocker                                            12 (8)
  Calcium channel blocker                                 6 (4)

Continuous variables are expressed as means and standard deviation.

###### 

Phenotypic characteristics and status of NKX2-5 mutations of the affected pedigree members.

  Subject information   Phenotype   Electrocardiogram   Echocardiogram   Genotype                                
  --------------------- ----------- ------------------- ---------------- ------------ ---- ----- ----- ---- ---- -------
  Family 1                                                                                                       E21Q
  I-1                   M           71                  52               Permanent    69   96    454   39   62   +/-
  II-2                  F           46                  34               Persistent   72   98    416   37   66   +/-
  II-3                  M           43                  40               Paroxysmal   70   90    449   35   64   +/-
  Family 2                                                                                                       T180A
  I-1                   M           65                  26               Permanent    66   110   458   42   60   +/-
  II-4                  F           40                  32               Paroxysmal   70   98    393   33   62   +/-

AF: atrial fibrillation, F: female, M: male, QTc: corrected QT interval, LAD: left atrial dimension, LVEF: left ventricular ejection fraction, +: present, -: absent.

###### 

NKX2-5 sequence variations identified in this study.

  Location   Nucleotide    Amino acid   Allele frequency   
  ---------- ------------- ------------ ------------------ ------------------
  Exon 1     c.61G\>C      p.E21Q       (0.003) 1/292      (0.000) 0/1400
  Exon 1     c.63A\>G      p.E21E       (0.223) 65/292     (0.259) 362/1400
  Exon 2     c.538A\>G     p.T180A      (0.003) 1/292      (0.000) 0/1400
  Exon 2     c\. 606C\>G   p.L202L      (0.021) 6/292      (0.016) 23/1400
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